Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLCTBP)

Drug Name

VTX-2337 Drug Info

Synonyms

Motolimod; 926927-61-9; VTX-2337; Motolimod (VTX-2337); UNII-WP6PY72ZH3; VTX-378; VTX 2337; WP6PY72ZH3; AK171372; Motolimod [USAN:INN]; Motolimod (USAN/INN); SCHEMBL254984; GTPL9026; CHEMBL3301618; KS-00000SZB; DTXSID10239107; MolPort-039-136-930; EX-A1102; BCP16667; ZINC34946588; s7161; AKOS025289797; SB16930; DB12303; HY-13773; KB-146010; J3.657.311B; D10716; 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Allergy	4A80-4A85	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 16049404
CAS Number: CAS 926927-61-9
TTD Drug ID: DMLCTBP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Toll-like receptor 8 (TLR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[3]
Selgantolimod	DMST4OR	Hepatitis B	1E51	Phase 2	[4]
Afimetoran	DM3HN3U	Systemic lupus erythematosus	4A40.0	Phase 2	[5]
NKTR-262	DMYR8LF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
CPG 52364	DMVDYTG	Systemic lupus erythematosus	4A40.0	Phase 1	[7]
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[8]
MEDI9197	DM0J7UR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
SBT6050	DMHBD3T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
VTX-1463	DM4ZIRK	Allergic rhinitis	CA08.0	Phase 1	[11]
DN1508052	DM0JT9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01666444) VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337).
3	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
4	Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
6	Clinical pipeline report, company report or official report of Nektar Therapeutics.
7	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
8	Clinical pipeline report, company report or official report of CureVac.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Clinical pipeline report, company report or official report of Silverback Therapeutics.
11	VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
12	Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.